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Abstract
Background: Numerous immune genes are epigenetically silenced in tumor cells and agents such
as histone deacetylase inhibitors (HDACi), which reverse these effects, could potentially be used
to develop therapeutic vaccines. The conversion of cancer cells to antigen presenting cells (APCs)
by HDACi treatment could potentially provide an additional pathway, together with cross-
presentation of tumor antigens by host APCs, to establish tumor immunity.
Methods: HDACi-treated B16 melanoma cells were used in a murine vaccine model, lymphocyte
subset depletion, ELISpot and Cytotoxicity assays were employed to evaluate immunity. Antigen
presentation assays, vaccination with isolated apoptotic preparations and tumorigenesis in MHC-
deficient mice and radiation chimeras were performed to elucidate the mechanisms of vaccine-
induced immunity.
Results: HDACi treatment enhanced the expression of MHC class II, CD40 and B7-1/2 on B16
cells and vaccination with HDACi-treated melanoma cells elicited tumor specific immunity in both
prevention and treatment models. Cytotoxic and IFN-γ-producing cells were identified in
splenocytes and CD4+, CD8+ T cells and NK cells were all involved in the induction of immunity.
Apoptotic cells derived from HDACi treatments, but not H2O2, significantly enhanced the
effectiveness of the vaccine. HDACi-treated B16 cells become APCs in vitro and studies in
chimeras defective in cross presentation demonstrate direct presentation in vivo and short-term
but not memory responses and long-term immunity.
Conclusion: The efficacy of this vaccine derives mainly from cross-presentation which is enhanced
by HDACi-induced apoptosis. Additionally, epigenetic activation of immune genes may contribute
to direct antigen presentation by tumor cells. Epigenetically altered cancer cells should be further
explored as a vaccine strategy.
Background
Modified tumor cells can induce tumor-specific immunity
and, in certain models, activate both adaptive and innate
immune responses [1]. However, in some mouse models
and the vast majority of human cancers, the tumor vac-
cines currently employed have not been successful. This
may be attributed to a failure of adequate stimulation of
appropriate components of immunity and/or tolerance to
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gies have focused on enhancing a cytotoxic T cell (CTL)
response. Activation of both T-helper cells and CTLs is
achieved primarily through cross-presentation of tumor
antigens by professional antigen presenting cells (APCs)
[2]. Antigens from apoptotic cells have been reported to
be a preferred vehicle for activating tumor immunity,
rather than tolerance, through cross-presentation by APCs
[1,3]. Direct antigen presentation by tumor cells could
potentially activate T cells provided the tumor cells can
deliver an MHC-restricted antigen-specific signal together
with appropriate costimulatory signals [4-6]. However,
the role of tumor cells as APCs has not been well defined.
Nevertheless, MHC class I mediated direct priming of
CTLs has been observed in an engineered tumor model
which is dependent on the density of MHC/peptide com-
plexes and the expression of B7 costimulatory molecules
on tumor cells [7]. Moreover, transfection of MHC class II
negative tumors with MHC class II and B7-1 genes pro-
duces a cellular vaccine capable of eliciting immunity [8].
MHC class II positive tumor cells are also effective APCs in
vivo and can present novel endogenous antigenic pep-
tides not presented by host APCs [5]. Furthermore, trans-
fection of tumors with class II transactivator (CIITA)
elicits MHC class II expression and can restore the ability
of certain tumor cells to present antigen and induce
immunity [9,10]. Although cross-presentation is the
major mechanism generating immunity [2,3], the above
studies on tumors as APC suggest that, at least in certain
tumors, direct antigen presentation could provide an
alternative or additional pathway in tumor immunity. An
important issue is whether direct presentation can be
enhanced in vivo and become a quantitatively significant
component of tumor immunity.
Tumor escape has been attributed to selection of tumor
cells with mutations in genes involved in both the initia-
tion and effector phases of immunity [11]. Recent evi-
dence also suggests that tumor cells may exploit
epigenetic silencing of immune genes to escape immune
destruction [12]. Epigenetic repression of immune genes
in tumors was first suggested for MHC class II genes and
CD40, which are infrequently mutated although often
deficient in tumors [13]. A number of other immune
genes, including MHC class I, components of the class I
peptide presentation pathway (TAP1, TAP2, LMP2, LMP7
and Tapasin), B7-1/2, NKG2D ligands and certain tumor
antigens, are also silenced by chromatin in multiple
tumor types [12,14].
Covalent modifications of chromatin are well established
regulators of gene expression and an array of epigenetic
alterations, including acetylation and methylation, have
been shown to target histones [15]. Histone acetylation
induced by histone deacetylase inhibitors (HDACi) fre-
quently increases accessibility of transcription factors to
promoter sites and results in enhanced gene transcription,
although some genes are inhibited by HDACi. The HDACi
trichostatin A (TSA) regulates the expression of ~5% of the
genome [16]. HDACi treatments have been used in clini-
cal trials on the basis of their ability to induce differentia-
tion and apoptosis of tumor cells [17]. HDACi-treated
tumor cells have also been successfully employed in a
murine tumor vaccine model [4]. Reversal of gene silenc-
ing by HDACi treatment can convert a plasma cell tumor
to an APC, in vitro, through upregulation of MHC class II
and costimulatory molecules [4,18]. Moreover, HDACi
treated melanoma tumor cells can mediate direct antigen
presentation via MHC class I, which stimulates IFN-γ-pro-
ducing T cells in vitro [14]. The present study was con-
structed to determine the mechanisms involved in
immunity generation by TSA-treated melanoma vaccines
and whether this epigenetically modified tumor cell vac-
cine is effective in a treatment model.
Materials and methods
Cells, mice and reagents
Mouse B16 melanoma, EL4 thymoma cell lines and hybri-
doma GK1.5, 2.43 and 53-6.7 cells (ATCC, Manassas, VA)
were maintained in culture as specified. Six to eight week
old female C57BL/6 (B6) (NCI, Bethesda, MD), MHC
class I deficient B6.129-β2mtm1 [class I-/-], class II deficient
B6.129-H2dlAb1-Ea (class II-/-) (Jackson Laboratory, Bar Har-
bor, ME), class I and class II double deficient B6.129-
Aββtm1-β2mtm1 (class I-/--II-/-) (Taconic, Germantown, NY)
and ovalbumin-specific I-Ab-restricted TCR transgenic
(OT-II) (Protul Shrikant, RPCI, Buffalo, NY) mice were
maintained in the Department of Laboratory Animal
Resources at RPCI. Principles of laboratory animal care
(NIH publication 85-23, revised 1986) were followed and
all work was carried out under RPCI IACUC approval. TSA
(Wako Biochemical, Richmond, VA), H2O2 (Sigma, St.
Louis, MO) and mouse IL-2 (R&D System, Minneapolis,
MN) were diluted in ethanol, water and PBS containing
0.5% BSA, respectively.
Flow cytometry
R-Phycoerythrin conjugated anti-mouse I-Ab, H-2Db,
CD4, CD40, CD80, CD86 and Pan-NK (DX5), FITC con-
jugated anti-mouse I-Ab and CD3, PE-Cy5.5 conjugated
anti-mouse CD8 and CD11c mAb, isotype controls
matched to each antibody (Pharmingen, San Diego, CA)
and FITC conjugated annexinV (Caltag, Burlingame, CA)
were used in flow cytometry experiments as previously
described [4]. The gated cell populations included both
apoptotic and non-apoptotic cells. In all preparations uti-
lized here, the adherent cells studied were >95% viable by
trypan blue exclusion.Page 2 of 12
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TSA-treated or untreated B16 cells (1 × 105 trypan blue
negative adherent cells) were injected s.c. in the ventral
trunk of the mice. This tumor challenge dose is 10 fold
higher than the minimum number of untreated cells
required to generate palpable tumor in 100% of mice
within 3 weeks after injection. Treated cells were assayed
prior to injection to ensure consistency between experi-
ments in MHC and costimulatory molecule expression as
well as apoptosis. Tumors were measured every 3 days and
mice were euthanized when tumor diameter reached 1
cm. After 40 days, all tumor-free mice were re-challenged
s.c. with untreated B16 (1 × 105) cells in the opposite site
and observed for another 60 days. In addition to palpable
tumor measurement, the absence of evidence of tumor in
immune mice was confirmed by visual inspection. At the
end of the study period (100 days after vaccination), a
mouse from each group of tumor-free mice was eutha-
nized and the tumor inoculation sites and regional lymph
nodes dissected and examined for evidence of tumor (no
visible tumor nodule or other evidence of tissue aberra-
tion) and compared with a palpable tumor-bearing
mouse (visible tumor nodules in lymph nodes). Some
tumor-free B6 mice were re-challenged with EL4 (1 × 104)
cells simultaneously as a control for tumor specificity. For
the treatment model, B6 mice bearing palpable (~0.5
mm) B16 tumor, 5 days after s.c implantation in the
trunk, were vaccinated with TSA- treated and irradiated
(2000 Gy) B16 cells in the opposite side. Groups of
tumor-bearing control mice received irradiated B16 cells
or were left untreated. Mice that became tumor-free were
re-challenged 42 days latter with wild type B16 in the
trunk and observed for another 40 days.
Cytotoxicity assays
To determine tumor immunity, tumor-free mice, 30 days
after vaccination with TSA-treated B16 cells, were re-chal-
lenged with untreated B16 cells and observed for an addi-
tional 15 days. Spleens isolated from three immune or
control mice were disrupted and splenocytes were puri-
fied over nylon wool (Polyscience, Warrington, PA). Non-
adherent lymphocytes (5 × 105) were re-stimulated with
TSA-treated (500 nM for 48 h) and irradiated (200 Gy)
tumor cells (2.5 × 105) in RPMI-1640 with IL-2 (10 U/
ml). After 4 days, T-cell-enriched (>90%) viable cells were
isolated after centrifugation through Ficoll-Paque and the
level of anti-B16 cytotoxicity was determined utilizing a
standard 4.5 h 51Cr-release assay [4].
ELISpot assays
The mouse IFN-γ ELISpot kit (BD Bioscience, San Diego,
CA) was used to determine antigen specific IFN-γ-secret-
ing cells in spleens of immune mice as described [19].
Briefly, RBC-depleted splenocytes (1 × 106 cells/well) iso-
lated from immune and control mice were incubated in
triplicate wells with B16 tumor cell lysate (~8 × 104 cell
lysate/well) or 5 µM mgp10025–33 peptide (Invitrogen,
Grand Island, NY) for 24 h. IFN-γ spots were developed
with AEC substrate and counted using a Zeiss Imaging sys-
tem. B6 mice bearing palpable tumor 15 days after inocu-
lation of untreated B16 (1 × 105 cells) and naïve mice were
used as controls. Splenocytes (2 × 105 cells/well) from
naïve mice treated with PMA (40 ng/ml) and Ionomycin
(1 µM) served as positive control. For in vitro antigen
presentation assays, popliteal lymph node T cells (2 ×
105), isolated from ovalbumin-primed OT-II mice and
purified magnetically (Pan T cell isolation kit, Miltenyi,
Auburn, CA), were assayed in triplicate with TSA-treated
(500 nM for 48 h) or untreated B16 cells (1 × 105) for 24
h. Splenocytes isolated from OT-II mice were used as con-
trol APCs. Tumor cells and splenocytes were pulsed with
ova-peptide322–338 or the control E333A ova-peptide322–
338 (10 µM) and irradiated (2000 Gy and 30 Gy respec-
tively) before use in the ELISpot assays to measure IFN-γ-
secreting T cells.
In vivo depletion studies
Anti-CD4 (GK1.5) and CD8 (2.43) hybridomas were
grown i.p. in SCID mice and ascites fluid was partially
purified by ammonium sulfate precipitation. To deplete
CD4+ or CD8+ T cells, B6 mice were injected i.p. with CD4
or CD8 mAb (200 µg in 200 µl PBS/mouse), given at day
-2, 0, +2, +4, +8 and +14. Rabbit anti-asialoGM1 γ-globu-
lin (Wako), reconstituted in water and diluted in PBS, was
used for NK cell depletion using the same schedule. Con-
trol mice received purified rat IgG (Chemicon Interna-
tional, Temecula, CA). Control and depleted mice were
vaccinated with TSA-treated B16 cells after the 2nd dose of
antibody injection and observed for 30 days. Depletion
was assessed on the day of vaccination and a week later by
flow cytometric analysis of splenocytes for CD3+CD4+,
CD3+CD8+ T cells and DX5+ NK cells.
Bone marrow chimera generation
Bone marrow (BM) cells were harvested from femur and
tibia of groups of donor (B6 and class I-/--II-/-) mice by
flushing the bones with RPMI-1640. RBCs were lysed
using Tris-buffered ammonium chloride and single cell
suspensions were obtained by passing BM cells through a
cell strainer [20]. T cells were depleted from BM prepara-
tions by incubation with CD8 (53-6.7) and CD4 (GK 1.5)
mAb (1:10 dilution) for 60 min at 4°C, followed by lysis
with low-tox-M rabbit complement (Cederlane, Ontario,
Canada) for 90 min at 37°C in 5% CO2 incubator [21]. In
preliminary experiments, BM cells after treatment with
hybridoma supernatants (53-6.7 or GK1.5) were analyzed
by flow cytometry using CD3, CD4 (L3T4) and CD8
(5H10) mAb to confirm the depletion of CD3+CD4+ or
CD3+CD8+ T cells. One day before BM infusion, recipient
B6 mice were injected i.p. with a single dose anti-Page 3 of 12
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vent NK mediated rejection of BM. The recipient mice
were exposed to 11 Gy total body irradiation (TBI) admin-
istered in two treatments 3 h apart from a 137Cs-radiation
source on the day of BM infusion. A total of 5 × 106 BM
cells from donor mice were injected into the tail vein of
each recipient. Chimeras were provided with water con-
taining 2 mg/ml neomycin sulfate for 4 weeks after irradi-
ation. Splenocytes, isolated from irradiated mice 2 days
after TBI, were analyzed by flow cytometry to confirm the
elimination of CD11c+ APCs and CD3+ T cells and >99%
elimination was observed. To obtain a dendritic cell (DC)
enriched APC population, low-density splenocytes were
isolated by collagenase digestion [22]. At 4–8 weeks after
BM transplant, chimerism was evaluated using PBLs and
splenocytes isolated from chimeric mice.
Isolation of apoptotic tumor cells
Apoptotic B16 cells were isolated using annexinV
microbead kit, MS separation column and magnetic sepa-
rator (Miltenyi, CA) according to the manufacturer's pro-
tocol. Briefly, TSA or H2O2-treated B16 cells were labeled
with annexinV microbead for 15 min at 6–12°C and
passed through a separation column in a magnetic field.
AnnexinV positive (an+) apoptotic cells were retained in
the column while annexinV negative (an-) non-apoptotic
cells ran through. Apoptotic cells were eluted after
removal of the column from the magnetic field.
Results
Enhanced expression of MHC class II and costimulatory 
molecules on melanoma cells after TSA treatment
Previously we showed that TSA treatment elicits the
expression of MHC class II and costimulatory molecules
on the mouse plasma cell tumor J558 and that vaccina-
tion with epigenetically altered tumor cells generates
tumor-specific immunity [4]. To extend this to another
tumor and to further analyze the mechanisms involved in
immunity generation we used the MHC class II negative
B16 melanoma. To determine the cell surface expression
of MHC class I, class II, CD40, CD80 and CD86 in rela-
tion to apoptosis induction, TSA-treated (50 nM-1 µM,
12–48 h) adherent (~95% viable) B16 cells were analyzed
by flow cytometry. The conditions inducing maximal
expression are presented in Figure 1A. This Figure demon-
strates enhancement of the expression of MHC class II,
CD40 and CD86 on B16 cells at 24 h and 48 h of TSA
treatment. TSA treatment also slightly enhanced the low-
level expression of class I found on untreated cells. Treat-
ment with 500 nM TSA for 48 h, a condition that pro-
duced 46% an+ cells in the adherent B16 population, in
addition to class II, CD40 and CD86 induced low-level
expression of CD80. TSA-treated B16 cells retained
enhanced expression of these genes over 24 h after with-
drawal of treatment in vitro (data not shown). These
results demonstrate that TSA treatment induces apoptosis
and elicits expression of class II and costimulatory mole-
cules on B16 tumor cells similar to the results previously
reported on the J558 plasmacytoma [4].
Durable immunity generated by epigenetically altered 
melanoma cell vaccination
To determine whether TSA treatment altered tumorigenic-
ity and immunogenicity, B16 cells treated with different
concentrations of TSA were inoculated into mice. As
shown in Table 1, nearly all control and 90% of the 250
nM TSA treated B16 (~20% an+ cells) injected mice devel-
oped tumors. Using 500 nM TSA (24 h) treated B16
(~40% an+ cells), 30% of the mice injected were tumor-
free for more than 40 days. However, when mice were
inoculated with B16 cells treated with 500 nM TSA for 48
h (~50% an+ cells), 80% of the mice were tumor-free after
10 days, by which time all controls had developed
tumors, and more than 60% of the mice remained tumor-
free for over 40 days (Table 1 and Figure 1B). When
tumor-free immune mice were re-challenged with
untreated B16, 100% of the TSA-treated B16 vaccinated
mice showed lasting immunity (Figure 1C). The immu-
nity generated by TSA-treated B16 vaccination is tumor
specific as the unrelated EL4 thymoma developed tumor
in 100% of the immune mice (data not shown). In similar
experiments, B16 cells treated with high dose (750 nM for
48 h) TSA, containing ~90% an+ cells, demonstrated
immunity in 40% of the mice after vaccination (data not
shown). This high dose was associated with greater
number of an+ cells did not improve the effectiveness of
the vaccine. These results indicate that, similar to the TSA-
treated plasmacytoma vaccine, TSA-treated melanoma
cells generate immunity and preparations containing
approximately 50% an+ cells were most effective in induc-
ing tumor specific lasting immunity [4].
Induction of cytotoxic and IFN-γ secreting lymphocytes in 
immune mice
To determine whether CTLs were elicited in immune
mice, T-cell-enriched splenic lymphocytes were isolated
from TSA-treated B16-vaccinated mice that remained
tumor-free after re-challenge and assessed for their ability
to lyse untreated B16 cells. As shown in Figure 2A, splenic
lymphocytes derived from immune mice displayed sub-
stantial B16 lytic activity (26%) compared with spleno-
cytes derived from control mice (<2%) at an effector:
target ratio 50:1. The cytotoxic lymphocytes induced by
TSA-treated melanoma vaccination were tumor specific,
since lysis of the unrelated target EL4 (1%) was signifi-
cantly lower than that of B16 (Figure 2A).
ELISPOT assays were employed to measure IFN-γ produc-
tion by cytotoxic lymphocytes from immune mice. As
shown in Figure 2B, splenocytes derived from mice immu-Page 4 of 12
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TSA treatment enhances apoptosis and immune gene expression on melanoma cells and TSA-treated vaccines generate immu-nityFigure 1
TSA treatment enhances apoptosis and immune gene expression on melanoma cells and TSA-treated vaccines generate immu-
nity. A) B16 cells were stained with mAb, isotype controls and annexinV after treatment with TSA and analyzed by flow cytom-
etry for the expression of MHC class I, class II, CD80, CD86 and CD40. Isotype controls are shown as shaded peaks and heavy 
lines represent expression determined by specific mAb staining. Values indicated in the histograms are the percent of cells pos-
itive for the respective mAb relative to the isotype staining. The data presented here are representative of more than three 
independent experiments. B) Kaplan-Meier plot of B6 mice (10 in each group) inoculated with TSA-treated (500 nM for 48 h) 
or untreated B16 cells in the trunk. C) Durable immunity in 100% of the immune animals. Tumor-free mice, 40 days after vac-
cination with TSA-treated B16, were re-challenged with untreated B16 cells and observed for another 60 days. The number of 
tumor-free mice compared to total numbers used in each treatment group is shown in parentheses.
Journal of Translational Medicine 2007, 5:64 http://www.translational-medicine.com/content/5/1/64nized with TSA-treated B16 and challenged with untreated
tumor cells showed significant increases in the numbers
of IFN-γ-producing cells after B16 cell lysate or mgp10025–
33 peptide stimulation compared to splenocytes derived
from naive mice. The number of IFN-γ-producing cells
found in splenocytes isolated from B16 tumor-bearing
mice was significantly lower than the immune mice.
PMA/Ionomycin treatment induced a high number of
IFN-γ-producing cells in splenocytes isolated from naïve,
tumor-bearing and immune mice. The presence of cyto-
toxic and IFN-γ-producing cells in the spleens of immune
mice, together with the demonstration of long-term
immunity after vaccination with TSA-treated B16 cells,
suggest that epigenetically altered tumor cells are capable
of inducing cell mediated tumor specific effectors and
immunity.
Involvement of CD4+, CD8+ T cells and NK cells in 
immunity induced by epigenetic vaccine
To determine the role of CD8+ and CD4+ T cells in immu-
nity, MHC double knockout class I-/--II-/- and single knock-
out class I-/- or class II-/-mice were used in tumorigenesis
experiments, since these MHC disrupted mice lack the
related subset of mature T cells (data not shown) [23]. The
incidence of tumor rejection in class I-/--II-/-, class I-/- and
class II-/- mice (Figure 2C-11%, 11%, 31% tumor-free
respectively) 40 days after TSA-treated B16 inoculation, is
significantly lower than in immunocompetent B6 mice
(73% tumor-free). Although, the percentage of tumor-free
mice in the class II-/- group is numerically higher than the
class I-/- group, the difference was not statistically signifi-
cant (p = 0.08). In subsequent re-challenge with untreated
B16, all the MHC deficient mice developed tumors (data
not shown) while immunocompetent mice remained
tumor-free.
To more specifically evaluate the contribution of T cell
subsets to protective immunity generated by TSA-treated
tumor cell vaccination, in vivo depletion was performed.
Calculation of the total number of CD4+ and CD8+ T cells
in each spleen, isolated from the respective T cell depleted
mice, compared to undepleted control spleens, demon-
strated >95% depletion of specific subsets (data not
shown). Figure 2D shows that the percentage of tumor-
free mice in CD8+ or CD4+ T cell depleted groups (12.5%
and 37.5%, respectively), 3 weeks after vaccination with
TSA-treated B16 cells, is significantly lower than the con-
trol groups (~75%). NK cells can be responsible for tumor
rejection by direct lysis of tumor cells and by producing
cytokines that recruit and activate DCs and T cells [24,25].
Depletion of NK cells prior to vaccination, as shown in
Figure 2D, completely abrogated the anti-tumor effect of
TSA-treated B16 vaccination. These results demonstrate
that CD4+, CD8+ T cells and NK cells are all required for
generation of the immune response by TSA-treated B16
cells and that NK cells are particularly important in tumor
rejection. However, the TSA-treated B16 tumorigenesis
data from T cell deficient class I-/--II-/- mice and our previ-
ous studies in SCID mice with TSA-treated plasmacytoma
[4] suggest that NK cells alone, in the absence of T cells,
are not sufficient to induce effective anti-tumor immunity
in these epigenetic vaccine models.
Antigen presentation by TSA treated tumor cells in vitro 
and in vivo
In order to determine the mechanism of epigenetic vac-
cine induced immunity, we further explored whether B16
melanoma cells are converted to APC following TSA treat-
ment. Figure 3A demonstrates that TSA-treated B16 cells
can present ova-peptide322–338 to OT-II T cells in the con-
text of MHC class II in vitro. In view of these studies and
to determine the role of direct antigen presentation in elic-
itation of the immune response by epigenetic tumor cell
vaccination in vivo, we developed MHC double knockout
BM (DKO-C) chimeras using class I-/--II-/- donors and irra-
diated B6 recipients. Control BM (B6-C) chimeras were
produced using immunocompetent B6 donors and irradi-
ated B6 recipients. Both class I and class II expressing
APCs were significantly reduced in DKO-C chimeras and
they were repopulated with CD4+ and CD8+ T cells (see
Additional file 1). Since MHC class I and/or class II medi-
ated antigen presentation by BM derived APCs initiates
cross priming of T cells [1], the DKO-C chimeras are
expected to have lost the ability to present antigen from
cross priming. B6-C chimeras did not show a deficiency in
APC MHC expression, were re-populated with T cells (see
Additional file 1) and were expected to have intact cross-
presentation capability from both MHC pathways. When
Table 1: Tumorigenesis in the epigenetic melanoma vaccine model
Treatmenta % AnnexinV+ cells/inocula Number of mice that 
developed tumor (total)b
% Tumor-free mice after 40 days
Untreated ~10 32 (33) 3
250 nM TSA (24 h) ~20 9 (10) 10
500 nM TSA (24 h) ~40 7 (10) 30
500 nM TSA (48 h) ~50 19 (48) 61
a TSA-treated (concentrations and length of treatment as indicated) or untreated B16 cells (1 × 105 trypan blue negative adherent cells) were 
inoculated s.c. in B6 mice. b The total number of mice used per treatment group is shown in parentheses.Page 6 of 12
(page number not for citation purposes)
Journal of Translational Medicine 2007, 5:64 http://www.translational-medicine.com/content/5/1/64these chimeras were inoculated with TSA-treated or
untreated B16 cells, 50% of control chimeras and 37.5%
of DKO-C chimeras remained tumor-free 10 days after
inoculation of TSA-treated B16 cells while all the B6-C
and DKO-C chimeras had developed untreated B16
tumors (Figure 3B). Delayed tumor generation, at day 10,
in B6-C (p <0.01) or DKO-C chimeras (p <0.03) after
inoculation of TSA-treated cells was statistically signifi-
cant compared to B6-C or DKO-C chimeras injected with
untreated B16. These data demonstrate that, in the
absence of cross-presentation, tumor generation is
delayed suggesting that direct antigen presentation by
TSA-treated tumor cells may contribute to delayed tumor
TSA-treated B16 vaccine elicits cytotoxic and IFN-γ-produc-ing lymphocytes and requires T and NK ells in immunityFi ure 2
TSA-treated B16 vaccine elicits cytotoxic and IFN-γ-produc-
ing lymphocytes and requires T and NK cells in immunity. A) 
T-cell-enriched splenic lymphocytes isolated from immune or 
control mice after in vitro re-stimulation were analyzed in 
triplicate for cytotoxic activity using 51Cr-labeled untreated 
B16 or EL4 as targets. B) Splenocytes isolated from immune, 
B16 tumor-bearing or naive B6 mice were cultured in anti-
IFN-γ coated plates with B16 cell lysate or melanoma antigen 
mgp10025–33 peptide and IFN-γ secretion was detected by 
ELISpot assay. *, p <0.0008 (cell lysate stimulation) and **, p 
<0.03 (peptide stimulation) compared with splenocytes from 
tumor-bearing mice. PMA and Ionomycin treated splenocytes 
served as positive control. These experiments (A and B) 
were repeated 3 times with similar results. C) Reduced inci-
dence of TSA-treated (500 nM for 48 h) B16 tumor rejection 
in MHC deficient mice that lack CD4+ and/or CD8+ T cells 
compared with immunocompetent mice. The Kaplan-Meier 
plot shows tumor-free survival of class II-/- (n = 16), class I-/- (n 
= 18), class I-/--II-/- (n = 18) and immunocompetent B6 (n = 15) 
mice after s.c. vaccination with TSA-treated B16 (1 × 105 
cells). D) Depletion of CD4+, CD8+ T cells and NK cells 
reduces immunity generation by TSA-treated B16 cells. B6 
mice were depleted of CD4+ (n = 16), CD8+ (n = 8) T cells 
or NK cells (n = 8) by repeated injection of respective anti-
bodies (see Methods). Undepleted controls (n = 16) received 
IgG. All mice were observed for tumor growth after s.c. vac-
cination with TSA-treated B16 cells in the trunk.
TSA treatment converts B16 melanoma cells to APCsFigure 3
TSA treatment converts B16 melanoma cells to APCs. A) In 
vitro antigen presentation by TSA-treated (500 nM for 48 h) 
B16 cells. Purified T cells from OT-II mice were cultured 
with antigen-pulsed (ova-peptide322–338 or control peptide), 
irradiated B16 cells (TSA-treated or untreated) and spleno-
cytes (from OT-II mice as control APCs) in a standard ELIS-
pot assay to measure IFN-γ-secreting cells. B) Eight weeks 
after BM transplantation, control [B6-C] and MHC double 
knockout [DKO-C] chimeras were inoculated s.c. with TSA-
treated B16 (1 × 105 cells) in the trunk and tumor-free sur-
vival was recorded. Control groups of B6-C and DKO-C chi-
meras were injected with untreated B16 cells. The survival 
curve for these two groups were coincident; therefore a rep-
resentative plot [chimeras, untreated B16] showing the 
tumor-free survival of these controls is presented. Results 
from two independent experiments (four chimeras/group/
experiment) are presented in this figure.Page 7 of 12
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meras were able to provide the long-term protection after
vaccination with TSA-treated B16 cells that was demon-
strated by the immunocompetent mice (Figure 1). This
observation also suggests that the BM chimeras used for
these experiments, although repopulated with T cells, may
not be completely immunocompetent as has been noted
by others [26]. Additionally, a recent report suggests that
direct presentation by TSA-treated B16 cells may generate
partial activation of T cell effector function, but is unable
to provide long-term protection in the absence of other
signals [27]. This may, at least in part, explain the ability
in our chimeric experiments to elicit short-term but not
long-term immunity.
Role of apoptotic tumor cells in the generation of 
immunity
The tumorigenesis studies with B16 cells (Table 1)
showed that the highest level of immunity was obtained
using vaccine preparations containing apoptotic cells.
This raises the possibility that TSA treatment enhances
immunity, at least in part, by induction of apoptosis. To
further elucidate the role of apoptotic cells in the B16
model and the ratio of apoptotic to viable cells required
for optimal immunity, populations of apoptotic and non-
apoptotic adherent B16 cells were separated using annex-
inV magnetic beads. We also compared the effects of TSA-
apoptotic cells with those elicited by H2O2, a potent
inducer of apoptosis via the oxidative pathway [28]. The
dose of H2O2 was determined by titration of B16 cells
with H2O2 at various concentrations and incubation times
with apoptosis measured by flow cytometry. Flow cyto-
metric analysis of the separated TSA or H2O2-treated B16
populations showed that >99% of the cells in the apop-
totic fraction were an+ and >85% cells in the non-apop-
totic fraction were an- (data not shown). To determine
tumorigenicity and immunity, groups of mice were inoc-
ulated with TSA or H2O2-treated apoptotic cells, TSA-
treated non-apoptotic or mixed (50% TSA-treated apop-
totic + 50% TSA-treated non-apoptotic) B16 cells. As
shown in Figure 4A, 40% of mice that received mixed B16
inocula were tumor-free at day 20, while all the mice
injected with TSA-treated non-apoptotic or untreated B16
cells developed tumors. TSA or H2O2-treated apoptotic
cells did not replicate in vitro (data not shown) and did
not produce tumors in vivo (Figure 4A). To determine the
level of immunity induced, all tumor-free mice were chal-
lenged after 3 weeks with untreated B16 cells. The TSA-
treated live plus apoptotic 50:50 mixture generated a sig-
nificantly higher level of durable immunity (Figure 4B,
88% tumor-free) compared to the TSA-treated apoptotic
inoculums (30% tumor-free) and H2O2-treated apoptotic
cells failed to elicit long-term immunity. The lasting
immunity induced by TSA-treated apoptotic cells is statis-
tically significant compared to H2O2-treated apoptotic
cells and untreated controls (p <0.04). These data suggest
that TSA-treated apoptotic cells may play a role in immu-
nity and TSA-treated preparations containing ~50% apop-
totic cells, in addition to non-apoptotic cells, are most
effective in inducing long-term immunity. Importantly,
these data also suggest that generation of durable immu-
nity by annexinV positive tumor cells may vary depending
on the apoptosis-inducing agents [28].
Treatment with epigenetically altered melanoma vaccines 
suppresses growing tumors
To evaluate the potential of clinical translation of the TSA-
treated vaccine model, two sets of tumorigenesis experi-
ments were performed. Firstly, to eliminate tumor growth
from the vaccine inocula, we lethally irradiated tumor
cells before inoculation and found that 100% of the mice
Anti-tumor immunity generated by TSA-treated apoptotic B16 cellsFigur  4
Anti-tumor immunity generated by TSA-treated apoptotic 
B16 cells. A) Kaplan-Meier plot of B6 mice (10 mice/group) 
vaccinated s.c. with magnetically separated TSA-treated (500 
nM for 48 h) apoptotic (~99% an+), non-apoptotic (>85% an-
), mixed (50% an+ with 50% an-) or H2O2-treated (10 mM for 
4 h) apoptotic (~99% an+) B16 (1 × 105 cells) and observed 
for tumor-free survival. Control mice received untreated 
B16 cells. B) Tumor-free mice, 3 weeks after vaccination 
with TSA-treated apoptotic (n = 10), non-apoptotic (n = 8), 
mixed (n = 8) or H2O2-treated apoptotic (n = 10) B16 cells 
were re-challenged with untreated B16 (1 × 105 cells) s.c. in 
the opposite side of the trunk and observed subsequently for 
another 6 weeks. The data are presented as the percentage 
of tumor-free mice after tumor challenge.Page 8 of 12
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ated) did not develop tumor (data not shown). After 3
weeks, tumor-free mice from both groups were challenged
with wild type B16; 50% of the TSA-radiation group and
only 12.5% of the control-radiation group showed dura-
ble immunity (Figure 5A). These data suggest that killing
the TSA-treated tumor cells with radiation does not reduce
the vaccine efficacy. Additionally, to determine the effi-
cacy of the irradiated vaccine in a therapeutic model, pal-
pable B16 tumor-bearing mice were inoculated with TSA-
treated or untreated B16 cells (irradiated) on the opposite
side. As shown in Figure 5B and 5C, 100% of mice receiv-
ing a single injection of TSA-treated (irradiated) B16 vac-
cine were tumor-free at 42 days and 50% of them
remained tumor-free 40 days after wild type tumor chal-
lenge. In 75% of tumor-bearing mice, the tumor regressed
after injection with irradiated B16 cells (Figure 5B), but
none of them were protected against challenge with wild
type B16 (Figure 5C). These data demonstrate that vacci-
nation with TSA-treated (irradiated) tumor cells can sup-
press primary tumor growth as well as promote long-term
immunity in this treatment model.
Discussion
This study demonstrates that vaccination with TSA-treated
melanoma cells expressing both MHC class II and costim-
ulatory molecules can generate tumor-specific durable
immunity and that the vaccine is effective against an exist-
ing B16 tumor in a treatment protocol. The induction of
tumor immunity described here requires CD8+, CD4+ T
and NK cells. Experiments performed in MHC class I
knockouts and CD8+ T cell antibody-depleted mice sub-
stantially reduced the anti-tumor effects of the vaccine
thereby supporting the essential role of CD8+ T cells in
this model. Additionally, the partial abrogation of the
immune responses in class II knockout mice, the lack of
immunity in MHC double knockout mice and the tumor-
igenesis data in CD4+ T cell antibody-depleted animals
suggest that CD4+ T cells are also essential in the genera-
tion of immunity. The data from T cell deficient or
depleted mice together with the findings of cytotoxic and
IFN-γ-secreting lymphocytes in immune mice in associa-
tion with long term immunity demonstrate that a single
dose of the TSA-treated tumor cell vaccine is capable of
activating naïve T cells to generate cytotoxic effector and
memory T cells. Our results also showed that depletion of
NK cells completely abrogated immunity generation by
TSA-treated B16 cells suggesting that NK cells, together
with T cells, play an important role in initiation of immu-
nity following epigenetic vaccination.
The association of immunity with enhanced class II and
costimulatory molecule expression and in vitro activation
of antigen-specific CD4+ T cells by TSA-treated melanoma
cells is consistent with the hypothesis of direct antigen
Prevention and treatment of melanoma by TSA-treated (irra-diated) tumor cell vacci eFigure 5
Prevention and treatment of melanoma by TSA-treated (irra-
diated) tumor cell vaccine. A) Vaccination with TSA-treated 
(500 nM for 48 h) and irradiated (2000 Gy) B16 cells pre-
vents B16 tumor generation. Three weeks after s.c. inocula-
tion of TSA-treated [TSA-radiation] or untreated [radiation] 
B16 (1 × 105) cells in B6 mice (16 in each group); all tumor-
free mice were challenged s.c. with wild type B16 (1 × 105) 
cells and observed for 40 days. Percentage of tumor-free 
mice is presented in the Kaplan-Meier plot. B) Suppression 
of primary tumor growth by TSA-treated and irradiated 
melanoma vaccine. Groups of B6 mice bearing palpable B16 
(5 days tumor growth) were treated s.c. with TSA-treated 
and irradiated B16 [TSA-radiation] or untreated irradiated 
B16 (1 × 105 cells) [radiation] in the opposite side of the 
trunk. A group of tumor-bearing mice did not receive any 
treatment [no treatment]. The number of tumor-free mice 
compared to total numbers used in each group is shown in 
parentheses at 42 days after treatment. C) Induction of long-
term immunity in tumor-bearing mice treated with epigeneti-
cally altered melanoma vaccine. B16 tumor-bearing mice that 
became tumor-free following vaccine treatment were re-
challenged s.c. with wild type B16 (1 × 105 cells). Kaplan-
Meier plot shows tumor-free survival of mice in both TSA-
radiation and radiation groups after re-challenge.Page 9 of 12
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tion could be a component of tumor immunity is sug-
gested by: 1) the reported demonstration of direct
presentation in viral and other tumor model systems
[7,29]; 2) the effectiveness of tumor vaccines established
by transfecting tumor cells with MHC and costimulatory
genes [30]; and 3) the conversion of tumor cells to APCs
by epigenetic agents discussed above and previously
reported [14,18]. The substantial effectiveness of the TSA-
modified tumor cell vaccine shown here, together with
the delayed tumor generation data in MHC deficient chi-
meras, suggest a short-lived in vivo effect from direct anti-
gen presentation. Our view is that cross-presentation is
likely the major mechanism of T cell activation in most
tumors (as outlined by others and reviewed in [2]) but
that, in certain tumors and conditions, a component of
direct presentation may exist. The important issue is
whether clinically significant direct presentation can be
established by appropriate treatments designed to convert
a sizable portion of the tumor cells in the tumor bed to
APCs. Since tumors may have a billion or more cells when
first detected [31], converting even a small percentage of
cells could potentially have significant effects. Further-
more, we would expect that Treg cells and other immuno-
suppressive mechanisms might also repress direct
presentation. It remains to be determined whether combi-
nations of the epigenetic vaccine with other modalities,
such as adjuvants or anti-Treg antibody, can enhance the
efficacy of direct antigen presentation by tumors. Current
evidence suggests that sustained antigen presentation is
important in promoting immunity and that the duration
of antigen presentation is a major factor in activation of
memory T cells [32,33]. The short-term effects seen in vivo
in the direct presentation model could reflect the lack of
sustained antigen presentation. Further experiments are
required that include multiple injections, adjuvants with
sustained antigen release, further adjustments of amount
and concentration of the apoptotic population and other
procedures employed for DC vaccines directed at enhanc-
ing and maintaining MHC/peptide complex and main-
taining the adjuvant environment and activation state of
the tumor [33,34].
Since HDACi affect the expression of many genes [12], we
consider it likely that additional mechanisms other than
direct presentation may contribute to epigenetically
induced tumor immunity. In this regard, TSA treatment
can enhance the expression of NKG2D ligands [35] on
tumor cells, which may activate NK cell mediated
immune responses and synergize with CD28 in inducing
proliferation and IFN-γ production by CD8+ T cells [36].
However, whether TSA induction of NKG2D ligands is
mediated by chromatin or stress effects on tumor cells is
uncertain. In addition, although our data and other
reports suggest that NK cells can mediate immunity
against tumor cells expressing NKG2D ligand [37] or
MHC class I [38], the role of NK cells in generating a long-
lasting memory immune response after epigenetic vacci-
nation is uncertain. One possibility suggested by the strict
requirement for NK cells is that NK cells interact with
tumor cells treated with TSA (and expressing CD40) as
described for DC [39,40] and enhance antigen presenta-
tion [33].
Apoptotic tumor cells could potentially contribute to
immunity generation through several pathways. Previous
studies suggested that phagocytosis of apoptotic cells by
DCs in certain conditions can induce tolerance [41], while
other reports demonstrate that cross-presentation of anti-
gen from apoptotic tumor cells can generate tumor spe-
cific immune responses [42]. The experiments performed
with TSA-treated apoptotic B16 preparations demon-
strated that apoptotic tumor cells are capable of eliciting
long-term immunity. The induction of immunity by
apoptotic tumor cells has been related to their ability to
induce inflammation and to mature DC, in part owing to
the presence of heat shock proteins in apoptotic cell prep-
arations, especially those containing necrotic cells
[1,43,44]. Since apoptotic cells were defined by annexinV
binding in our study, the presence of an+ necrotic cells is
likely in TSA-treated apoptotic preparations. It has been
reported that apoptotic tumor cells produced by treat-
ment with TSA have different expression patterns of MHC
class II and costimulatory molecules compared to apop-
totic cells elicited by L-phenylalanine mustard, H2O2 andγ-irradiation [28]. Moreover the data presented here
shows that apoptotic tumor cell preparations produced by
TSA, but not H2O2, treatment generated long-term immu-
nity. The failure of the H2O2-treated apoptotic B16 cells to
enhance immunity demonstrates a selective effect of TSA-
treated apoptotic cells and suggests that apoptosis induc-
ing agents should be carefully evaluated for differential
effects in anti-cancer therapy. In this regard, recent evi-
dence suggests that apoptotic cell death due to caspase-3
activation results in the release of bioactive lipid mole-
cules, which promote DC maturation and pro-inflamma-
tory responses [45]. Since TSA may induce apoptosis in
certain tumor cells through a caspase-3 and mitochondria
dependent pathway [46], it is possible that TSA-treated
apoptotic B16 cells release bioactive lipids, which pro-
mote innate, perhaps TLR and NK mediated, immunity as
well as adaptive responses.
The reported enhancement of DC vaccine potency by the
addition of apoptosis promoting agents suggests a role for
apoptotic cells in synergizing with live cells in eliciting
immunity [47]. Our results showed that addition of TSA-
treated non-apoptotic cells to apoptotic (50% an- + 50%
an+) B16 inocula significantly improved the vaccine effi-
cacy. Therefore, in addition to the conversion of tumorPage 10 of 12
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producing high levels of antigen with an apoptotic adju-
vant-like effect could explain the superiority of the high
dose (500 nM) TSA-treated B16 vaccines compared with
lower doses of TSA and the H2O2-treated cells. Also, since
TSA alters chromatin and indirectly inhibits DNA methyl-
ation [48], it could potentially activate repressed endog-
enous tumor antigens, such as MAGE [49] and HMW-
MAA [50] that may serve as epigenetically induced tumor
antigens. Finally, HDACi modulates DNA damage (ATM/
ATR) [35] and MAPK pathways [51] and could therefore
serve as an intracellular adjuvant, which have been shown
to enhance DC vaccine potential [34].
The data presented here suggests that an autologus tumor
cell vaccine generated by HDACi in vitro is effective in
both preventative and treatment models. Further work,
currently in progress, will focus on obtaining more effec-
tive vaccines using different HDACi preparations, combi-
nation with adjuvant or anti-Treg as well as multiple
vaccinations. We would envision future clinical protocols
using this vaccine, most likely in combination with sur-
gery and/or other strategies, to treat recurrence and metas-
tasis of tumors. Clearly there are challenges and potential
problems in adapting a cell-based vaccine of this type to
the treatment of human cancer. If clinically effective vac-
cines could be developed, they would have the advantage
of being histocompatible with the host and applicable
without prior knowledge of the tumor antigens involved.
These studies also suggest that current therapies with epi-
genetic agents could affect host immunity to the tumor
and attention should be given to this aspect in ongoing
and future clinical protocols using these agents systemi-
cally.
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